These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16598882)

  • 1. Autoimmunity aids survival in melanoma.
    Senior K
    Lancet Oncol; 2006 Apr; 7(4):289. PubMed ID: 16598882
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmunity and immunotherapy for cancer.
    Koon H; Atkins M
    N Engl J Med; 2006 Feb; 354(7):758-60. PubMed ID: 16481646
    [No Abstract]   [Full Text] [Related]  

  • 4. [After removal of a malignant melanoma. Enhancing the immune system!].
    MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic significance of autoimmunity during treatment of melanoma with interferon.
    Gogas H; Ioannovich J; Dafni U; Stavropoulou-Giokas C; Frangia K; Tsoutsos D; Panagiotou P; Polyzos A; Papadopoulos O; Stratigos A; Markopoulos C; Bafaloukos D; Pectasides D; Fountzilas G; Kirkwood JM
    N Engl J Med; 2006 Feb; 354(7):709-18. PubMed ID: 16481638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant interferon therapy for melanoma.
    Hancock B; Wheatley K; Ives N; Gore M
    J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
    [No Abstract]   [Full Text] [Related]  

  • 9. [Autoimmunity induced by low doses of interferon in melanoma stage I].
    Ballanger F; Allix ML; Rimbert M; Audrain M; Muller JY; Dreno B
    Ann Dermatol Venereol; 2006; 133(6-7):543-8. PubMed ID: 16885841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant interferon for melanoma.
    Wheatley K; Ives N
    Ann Oncol; 2002 Aug; 13(8):1319-20; author reply 1320. PubMed ID: 12181258
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant interferon in the treatment of melanoma.
    Kirkwood JM
    Br J Cancer; 2000 May; 82(10):1755-6. PubMed ID: 10817514
    [No Abstract]   [Full Text] [Related]  

  • 12. How does interferon work? Does it even matter?
    Sondak VK
    Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
    J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 16. Node positive melanoma--a positive note?
    Kelly J; Kerin MJ
    Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
    Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
    [No Abstract]   [Full Text] [Related]  

  • 18. Melanomas reveal their nakedness: uncovered by interferon alfa.
    Arbiser JL; Bonner MY
    Arch Dermatol; 2009 May; 145(5):587-8. PubMed ID: 19451506
    [No Abstract]   [Full Text] [Related]  

  • 19. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
    Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
    Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
    [No Abstract]   [Full Text] [Related]  

  • 20. [Feasability and tolerance of adjuvant treatment of melanoma with immunotherapy according to Kirkwood protocol].
    Uwer L; Martin S; Geoffrois L; Schmutz JL
    Ann Dermatol Venereol; 2005 Jan; 132(1):50-1. PubMed ID: 15746611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.